PM BUZZ Report

Through our partnership with Diaceutics, we are pleased to offer the Personalized Medicine (PM) Buzz.

Compiled and curated from top global resources, the PM Buzz is a monthly snapshot of:

  • The latest news
  • Industry developments
  • Headline stories in the world of personalized (precision) medicine.

 

What’s happening in the PM industry…

  • FDA approval brings first gene therapy to the United States read on…
  • Gilead to buy Kite for promising cancer therapies in $12 billion deal read on…
  • A cancer conundrum: too many drug trials, too few patients read on…
  • Exosome Diagnostics, CareFirst partner to speed up coverage for diagnostic tests read on…
  • Cancer Treatment Centers of America, Foundation Medicine partner on precision medicine education initiative read on…
  • Bristol-Myers Squibb’s Opdivo nabs MSI-H colorectal cancer nod, but it can’t match Keytruda’s umbrella approval read on…
  • Invivoscribe releases LeukoStrat CDx FLT3 mutation assay as CE-marked IVD assay kit read on…
  • Direct detection of early-stage cancers using circulating tumor DNA read on…

Subscribe to receive future PM Buzz Reports.

 

Learn More About Diaceutics

Diaceutics is a global group of experts from the laboratory, diagnostic and pharmaceutical industries with the goal of helping pharmaceutical companies integrate diagnostic testing into their treatment pathways. Diaceutics is empowered through a real-time flow of testing data from their worldwide laboratory network which they use to help their pharma clients understand and leverage the diagnostic landscape. Learn more about Diaceutics.